CLBIO — Corline Biomedical AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK217.06m
- SEK200.05m
- SEK25.03m
Annual cashflow statement for Corline Biomedical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.54 | -7.29 | -6.91 | 2.33 | -1.79 |
| Depreciation | |||||
| Changes in Working Capital | -4.31 | 2.21 | 2.04 | -8.84 | 2.58 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.8 | -5.07 | -4.83 | -6.45 | 0.886 |
| Capital Expenditures | -4.84 | -8.8 | -9.62 | -9 | -10.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | 0.056 | 0 | 0 |
| Change in Net Investments | |||||
| Cash from Investing Activities | -4.84 | -8.8 | -9.56 | -9 | -10.6 |
| Financing Cash Flow Items | — | — | -3.51 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 13.9 | 0 | 47.1 | 0.026 | 0.537 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.79 | -13.9 | 32.7 | -15.4 | -9.2 |